ArticleBMC medical imaging2026
The utilization of myocardial perfusion imaging prior to coronary angiography to improve outcomes and cost-effectiveness of patients with stable coronary artery disease: a comparative cohort study in China.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe incremental value of myocardial perfusion imaging (MPI) before coronary angiography (CAG) for suspected or known stable coronary artery disease (SCAD) has not been validated in China. This study investigated the necessity of MPI for these patients regarding improvements in cardiac outcomes and cost-effectiveness in China.
methodsThe initial cohort comprised 7,437 patients with suspected or known SCAD between 2018 and 2019. After excluding patients with acute coronary syndrome, previous myocardial infarction (MI) and revascularization, enrolled patients were divided into the CAG group and the MPI group according to the initial strategy (CAG or MPI). Then, two groups were matched by propensity score. The cost, revascularization, MI, and all-cause mortality of patients were followed.
resultsThe MPI and CAG groups each included 130 patients after matching, with similar basic characteristics (P > 0.05). Significantly decreased cardiac events were observed in the MPI group compared to the CAG group (6 vs. 16, P < 0.05). Furthermore, the number of revascularization (5 vs. 12), MI (1 vs. 3), and all-cause mortality (0 vs. 1) in the MPI group was also lower. The Cox model showed that fewer patients in the MPI group had cardiac events (HR 0.27, 95% CI 0.10-0.71). Moreover, patients in the MPI group had fewer first-visit costs ($718 vs. $1389) and fewer downstream costs ($120 vs. $344) than those in the CAG group (P < 0.001).
conclusionsOur findings suggest that an MPI-first strategy is associated with fewer cardiac events and lower costs compared with an initial CAG strategy.
trial registrationNot applicable. This study is a retrospective analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.